15 November 2023 | Wednesday | News
Image Source | Public Domain | Repligen CEO Tony Hunt
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2022 Sustainability Report and related reporting index disclosures. Themed “Making an Impact”, the report highlights the company’s measurable progress across multiple environmental, social and governance (ESG) initiatives since its inaugural 2020 Sustainability Report, “Committed to Making a Difference”. Supporting the 2022 Sustainability Report is a Reporting Indexes document containing disclosures against the following frameworks: Global Reporting Initiative (GRI) Standards, Sustainability Accounting Standards Board (SASB), United Nations Sustainable Development Goals (UN SDGs), and Task Force on Climate-Related Disclosures (TCFD). See the Sustainability section of Repligen’s website for more information.
Tony Hunt, Chief Executive Officer at Repligen said, “Our initial Sustainability report published in 2021 elevated awareness in the company and prompted higher levels of action across the ESG spectrum. We saw strong ratings and rankings as a result and are pleased to share this next 2022 progress report, while continuing to work toward positively impacting some of our more challenging initiatives and collaboration-based goals.”
Dianne Heiler, Senior Director of Packaging and Head of Sustainability at Repligen said, “I’m proud to be part of the team at Repligen that is driving progress across multiple sustainability ambitions, with the full support and participation of our executive team and Board. As this report publishes, already we are expanding the scope of our efforts and will submit a commitment letter by year end 2023 to SBTi* to lower total GHG emissions in alignment with the latest climate science.”
Below are just a few of the 2022 Sustainability Report highlights. Report data is through year end 2022 unless otherwise noted.
*SBTi: Science Based Targets initiative
© 2023 Biopharma Boardroom. All Rights Reserved.